Objective To study drug retention and response rates in patients with axial spondyloarthritis (axSpA) initiating a first tumour necrosis factor inhibitor (TNFi).
Methods Data from 12 European registries, prospectively collected in routine care, were pooled. TNFi retention rates (Kaplan-Meier statistics), Ankylosing Spondylitis Disease Activity Score (ASDAS) Inactive disease (<1.3), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) <40 mm and Assessment of SpondyloArthritis International Society responses (ASAS 20/40) were assessed at 6, 12 and 24 months.
Results A first TNFi was initiated in 24 195 axSpA patients. Heterogeneity of baseline characteristics between registries was observed. Twelve-month retention was 80% (95% CI 79% to 80%), ranging from 71% to 94% across registries. At 6 months, ASDAS Inactive disease/BASDAI<40 rates were 33%/72% (LUNDEX-adjusted: 27%/59%), ASAS 20/40 response rates 64%/49% (LUNDEX-adjusted 52%/40%). In patients initiating first TNFi after 2009, 6097 patients was registered to fulfil ASAS criteria for axSpA, 2935 was registered to fulfil modified New York Criteria for Ankylosing Spondylitis and 1178 patients was registered as having non-radiographic axSpA. In nr-axSpA patients, we observed lower 12-month retention rates (73% (70%–76%)) and lower 6-month LUNDEX adjusted response rates (ASDAS Inactive disease/BASDAI40 20%/50%, ASAS 20/40 45%/33%). For patients initiating first TNFi after 2014, 12-month retention rate, but not 6-month response rate, was numerically higher compared with patients initiating TNFi in 2009–2014.
Conclusion A large European database of patients with axSpA initiating a first TNFi treatment in routine care, demonstrated that 27% of patients achieved ASDAS inactive disease after 6 months, while 59% achieved BASDAI <40. Four of five patients continued treatment after 1 year.
- outcomes research
- DMARDS (biologic)
Statistics from Altmetric.com
LMØ and CHB are joint first authors.
MLH and MØ are joint senior authors.
Handling editor Josef S Smolen
Contributors Study leads were CHB, LMØ, MØ and MLH. All authors took part in discussions around setting up the collaboration and planning this study. The study analysis plan was drafted by CHB, LMØ, MØ and MLH and all authors gave input and approved it. Data cleaning was performed by NSK, LMØ, CHB and overseen by MØ and MLH. Data analyses were conducted by NSK, CHB and LMØ. The manuscript was drafted by CHB, MMØ and MLH and the final version of the manuscript was revised and approved by all authors, who also approved submission.
Funding The EuroSpA collaboration was financially supported by Novartis. Novartis had no influence on the data collection, statistical analyses, manuscript preparation or decision to submit.
Competing interests LMØ: Novartis; CHB: Novartis; JA: has entered into agreements with Abbvie, BMS, Lilly, Merck, Pfizer, Roche, Samsung Bioepis, and UCB, mainly for safety monitoring via the Swedish ARTIS system, and received a travel reimbursement from Novartis. Karolinska Institutet has received remuneration for JA’s participation in meetings arranged by Pfizer and by Lilly; AC: AbbVie, Celgene, Eli Lilly, Janssen-Cilag, MSD, Novartis, Pfizer and UCB; HM: AbbVie, MSD, Novartis, Pfizer, Sanofi; FO: Abbvie, Novartis, Pfizer, Roche, UCB; EKK: none; DN: AbbVie, BMS, Lilly, MSD, Novartis, Pfizer, Roche, Sandoz, UCB; MJS: Abbvie, Biogen, Roche, Lilly, Pfizer, Novartis; Catalin Codreanu: AbbVie, Amgen, Angellini, Astra Zeneca, BMS, Egis, MSD, Pfizer, Richter, Roche, Sanofi, Servier, Teva, UCB, Zentiva; JGR: none; ZR: speaker or consulting fees from Abbvie, Amgen, Biogen, CellGen, Eli-Lilly, Jansen, Medis, MSD, Novartis, Pfizer, and Roche. BioRx.si has received funding for clinical research paid to Društvo za razvoj revmatologije from AbbVie, Celgene, Celtrion, Eli Lilly, Johnson & Johnson, Medis, MSD, Novartis, Pfizer and Roche; BG: Amgen, Novartis, Pfizer; MJN: Abbvie, Lilly, Pfizer, Novartis; KP: AbbVie, Roche, Pfizer, Amgen, Sanofi, Egis, BMS, UCB, MSD, Eli Lilly; TKK: AbbVie, Biogen, BMS, Celltrion, Egis, Eli Lilly, MSD, Mylan, Novartis, Oktal, Orion Pharma, Hospira/Pfizer, Roche, Sandoz, Sanofi and UCB; AB: Abbvie, Lilly, MSD, Novartis, Pfizer; MT: Abbvie, Amgen, Biogen, CellGen, Eli-Lilly, Jansen, Medis, MSD, Novartis, Pfizer, and Roche; FI: BMS, Pfizer, Abbvie, UCB, Roche, Celgene, Eli-Lilly, Hospira, Janssen, Merck; LHH: Novartis; MØ: Abbvie, BMS, Boehringer-Ingelheim, Celgene, Eli-Lilly, Hospira, Janssen, Merck, Novartis, Orion, Pfizer, Regeneron, Roche, UCB; MLH: Abbvie, Biogen, BMS, CellTrion, MSD, Novartis, Orion, Pfizer, Samsung, UCB.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
Data availability statement Data are available upon reasonable request.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.